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ABSTRACT
Fentanyl iontophoretic transdermal system
(ITS) [IONSYS, The Medicines Company,
Parsippany, NJ, USA] is a needle-free,
patient-controlled, postoperative opioid pain
management treatment. It is indicated for the
short-term management of acute postoperative
pain in adults requiring opioid analgesia in the
hospital. The safety and effectiveness of
fentanyl ITS for acute postoperative pain
management has been demonstrated in a
range of surgery and patient types studied in
seven phase 3 trials (three placebo-controlled
trials and four active-comparator trials). The
majority of the patients in the phase 3 trials had
undergone either abdominal/pelvic,
orthopedic, or thoracic surgery. Consistent
with the prescribing information, physicians
in clinical practice may treat patients with this
system following any type of surgery including
those that may not have been included in the
phase 3 trials. The purpose of this case series is
to illustrate how fentanyl ITS is being utilized
for postoperative pain management in
real-world clinical practice following a variety
of surgeries and in current pain management
protocols that may have evolved since the
completion of the phase 3 program. There are
seven cases from three clinical centers described
within this case series, each using fentanyl ITS
according to the prescribing information. The
surgery types included are bariatric (N = 3),
prostate (N = 2), colorectal (N = 1), and
perirectal abscess drainage (N = 1). A
systematic review of each patient chart was
conducted via a standardized retrospective
assessment by the clinicians who managed
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each patient. Additionally, each healthcare
professional was interviewed regarding their
overall experience and key learnings using
fentanyl ITS. Overall, fentanyl ITS was
effective and well tolerated in these case
reports in current-day clinical practice settings.
These case studies are informative about
fentanyl ITS use shortly after product approval
and set the stage for additional clinical research.
Keywords: Fentanyl; Iontophoresis; Patient-
controlled analgesia; Postoperative pain
management
INTRODUCTION
The management of acute postoperative pain
remains a priority for patients and health care
professionals; however, successful postoperative
pain management continues to be challenging
[1, 2]. Patient-controlled analgesia (PCA) was
introduced in the late 1970s to improve
postoperative pain management [3, 4]. It has
been demonstrated that patients who receive
PCA versus non-PCA analgesia have better pain
control and are more satisfied with their
method of pain control [5, 6].
New approaches, such as multimodal
analgesia and enhanced recovery after surgery
(ERAS) protocols, have been introduced to
improve pain management and patient
outcomes in the postoperative setting. At the
same time, patients who are presenting for
surgery have more co-morbidities (e.g.,
obesity) that make surgery and postoperative
care more challenging. In addition, the US
population is aging, and patients frequently
have chronic concomitant illness. Opioids
remain a cornerstone of postoperative pain
management; however, their use must be
balanced with the essential considerations
about safe use and combination with other
analgesic medications.
Fentanyl iontophoretic transdermal system
(ITS) [IONSYS, The Medicines Company,
Parsippany, NJ, USA] was approved by both
the US Food and Drug Administration (April
2015) and the European Medicines Committee
(November 2015) for the short-term
management of acute postoperative pain in
adult patients requiring opioid analgesia in the
hospital [7]. Fentanyl ITS can be used for a
maximum of 72 h of treatment, while each
individual system can be used for 24 h; for
example, patients who require 72 h of
treatment would require use of three systems
consecutively. Fentanyl ITS delivers
preprogrammed analgesic doses based on
patient control. As with intravenous
patient-controlled opioid analgesia, fentanyl
ITS is to be used only in patients who are alert
enough, have appropriate respiratory function
(e.g., high oxygen saturation levels, no
hypoventilation), and have adequate cognitive
ability to understand the directions for use.
Additionally, per the Prescribing Information,
fentanyl ITS is to be used after patients have
been titrated to an acceptable level of analgesia,
typically using alternate opioid analgesics.
While in clinical development, fentanyl ITS
was studied in seven phase III placebo and
active-controlled clinical trials [8–14]. In the
active-comparator trials, fentanyl ITS was
comparable to morphine IV PCA in terms of
pain-control efficacy and safety and was
superior for ease of care and nursing and
patient satisfaction [8, 10–12].
The objective of this case series was to
examine the ‘‘real-world’’ usage of the recently
approved fentanyl ITS. It is important to note
that, while this case series includes an
evaluation of surgical types that would have fit
the clinical study inclusion/exclusion criteria
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but may not have been specifically enrolled in
the original clinical trials (i.e., bariatric surgery),
fentanyl ITS is indicated across surgery types,
and all cases were managed consistent with the
Prescribing Information. This case series
provides an opportunity to review experiences
of early users of fentanyl ITS across a variety of
surgical and patient types in a clinical practice
setting.
METHODS
A systematic retrospective review of each patient
chart using a predefined set of variables was
performed via a standardized case assessment
form, with the data collected by interviewing
the treatingclinician(s).Additionally, eachhealth
care professional (HCP) being interviewed was
asked an additional set of questions surrounding
treatment decisions and clinical insights, and
those findings are also summarized. All data were
de-identified in the collection process. Sites were
selected who had clinical experience with
fentanyl ITS following approval and
representing different surgery types. The sites
selected the cases to be included in this case series.
Compliance with Ethics Guide
Data collected were all part of routine medical
practice and documented in the patient medical
records. Data were collected retrospectively by
reviewing the charts, and were all de-identified.
Therefore, Institutional Review Board approval
was not obtained.
RESULTS
This report includes seven cases from three sites.
The focus of this case series is postoperative
pain management using fentanyl ITS in the
hospital setting, with use consistent with the
Prescribing Information. The surgery types
included are bariatric (N = 3) [Forest Health
Medical Center, Ypsilanti, Michigan], prostate
(N = 2) [Universita¨tsklinik Gießen und Marburg
GmbH – Standort Marburg, Germany],
colorectal (N = 1) [Landmark Medical Center,
Woonsocket, RI], and perirectal abscess
drainage (N = 1) [Landmark Medical Center,
Woonsocket, RI]. The clinical course for each
case is described in the narratives below, which
are complemented by Table 1, which lists the
details of each case side-by-side.
BARIATRIC
Case 1
A 64-year-old female patient (BMI 37 kg/m2)
underwent a laparoscopic sleeve gastrectomy
and repair of a paraesophageal hernia. She
previously had a failed adjustable gastric band
and the band and port were removed during
this surgery. Her medical history included knee
osteoarthritis, hypertension, and
hypercholesterolemia. She had a history of
obstructive sleep apnea. She previously had
undergone bilateral total knee replacement
surgery. She had no preoperative history of
opioid tolerance. Fentanyl ITS was applied to
the chest once the patient was on the
medical-surgical unit mid-morning and was
removed the following day (also mid-morning)
just prior to a fluoroscopy of the upper
gastrointestinal tract. The patient
self-administered 34 doses of fentanyl over
24 h. She did not require any supplemental
opioid medication in conjunction with fentanyl
ITS. No concomitant medication was given for
opioid-related adverse events including no signs
of clinical relevant respiratory depression. The
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patient was transitioned to PO hydrocodone/
acetaminophen and discharged on that
regimen. The patient was very satisfied with
fentanyl ITS, describing it as easy-to-use and
preferable compared to her previous experience
with IV PCA.
Case 2
A 45-year-old female patient (BMI 58 kg/m2)
underwent a laparoscopic sleeve gastrectomy.
Her medical history included osteoarthritis and
obstructive sleep apnea. Surgical history
included three Cesarean sections. She had no
preoperative history of opioid tolerance.
Fentanyl ITS was applied to the chest once the
patient arrived on the medical-surgical unit
late-morning and was removed the following
day (early morning) just prior to a fluoroscopy
swallowing study of the upper gastrointestinal
tract. The patient self-administered 12 doses of
fentanyl over 20 h. This patient reported no
pain other than when walking, and consistently
reported being comfortable at rest. The patient
did not require any breakthrough medication,
although perhaps could have benefited from a
dose in conjunction with a single pain score of 7
out of 10 on a numeric rating scale (NRS). The
patient had nausea on postoperative day (POD)
1, and a single dose of ondansetron 4 mg IV was
administered approximately 2 h before the
system was removed. There were no signs of
respiratory depression. The patient was very
satisfied with the pain control while receiving
fentanyl ITS, noting that the pain control
improved over time and that the system was
very easy to use. However, it is important to
note that this patient did require some
additional training at the beginning of
treatment to ensure that the patient
‘‘double-clicked’’ the device to activate a dose,
but once that was completed she had no issues
with using the system. The patient was
discharged on PO hydrocodone/
acetaminophen. The treating clinicians
interpreted that this patient’s success with
fentanyl ITS showed that effectiveness of the
system was not related to BMI, considering the
particularly high BMI (58 kg/m2) in this patient.
Case 3
A 42-year-old female patient (BMI 45 kg/m2)
underwent a laparoscopic sleeve gastrectomy.
Her medical history included obstructive sleep
apnea andGERD. Shehadnopreoperative history
of opioid tolerance. Fentanyl ITS was applied to
the chest once the patient was on the
medical-surgical unit early afternoon and
removed the following day (mid-morning) just
prior toafluoroscopyof theuppergastrointestinal
tract. The patient administered 67 doses of
fentanyl over 20 h. The patient did not require
any breakthrough medication. No concomitant
medication was given for opioid-related adverse
events and there were no signs of respiratory
depression. The patient was discharged on PO
hydrocodone/acetaminophen. The patient was
very satisfied with the pain control while
receiving fentanyl ITS, and she reported that the




A 71-year-old female patient (BMI 30 kg/m2) with
acute diverticulitis underwent an elective
laparoscopic, robotic-assisted low anterior
resection (partial colon resection). She had a
14-year history of episodes of acute diverticulitis
with hospitalizations, each managed
non-operatively. Her medical history included
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diabetes, cardiovascular disease, chronic
obstructive pulmonary disease, gastroesophageal
reflux disease (GERD), depression, and anxiety.
She had no prior surgeries. In the post-anesthesia
care unit (PACU), she received 75 mcg of IV
fentanyl and 1 g of IV acetaminophen for pain
management. She was then transferred to the
medical-surgicalunit. She received standardbolus
doses of morphine sulfate PRN and 1 g of IV
acetaminophen every 6 h for pain management.
The usual standard of care (SOC) in the hospital
was IVPCA;however, therehadbeena shortageof
medication cartridges and the hospital had
switched to bolus doses of opioids for pain
management. Her pain was not well controlled
with this regimen.Due tohermedical history, she
was also being monitored for cardiovascular
events. On post-op day (POD) 1, she had an
asymptomatic elevated troponin. On POD 2 she
had a cardiac catheterization that showed an
occluded right coronary artery. The patient was
diagnosed with a silent myocardial infarction
(MI). Shortly thereafter, to achieve control of her
postsurgical pain, bolus doses ofmorphine sulfate
and IV acetaminophen were discontinued and
fentanyl ITS (which had just become available in
this hospital) was initiated for pain management
on POD 3. At the time that fentanyl ITS was
initiated, her pain score was 8 out of 10. Shortly
after initiation of fentanyl ITS, her pain scores
decreased and ranged between 3 to 5 during
fentanyl ITS treatment. Fentanyl ITS was
administered for 3 days (POD 3 to 6; total\72 h)
and then discontinued; the three devices were
applied to the upper arm on alternate sides. At
that point, she was transitioned to oral (PO)
hydrocodone/acetaminophen. The patient
received no additional opioids while on fentanyl
ITS. Throughout her stay, her diet was
uneventfully advanced from clear liquids to full
liquids, and then solids. There was some slight
skin redness where the system had been applied,
but it resolved without intervention by the next
day. On POD 7 she underwent a percutaneous
coronary intervention for further work-up of her
silent MI. She was discharged on POD 8. The
patient’s general impression of fentanyl ITS was
that she was very happy with the method of pain
control.
Case 5
A 63-year-old male patient (BMI 28 kg/m2) with
a painful perirectal abscess (right posterolateral,
multiloculated) was seen in the emergency
room and underwent emergent surgery that
evening, which involved an incision and
drainage of the abscess with 150 ml of pus
drained. He had a history of diabetes and
thyroid disease. In the PACU, he received 100
mcg of fentanyl. He was transferred to the
medical-surgical unit where the patient was
trained on fentanyl ITS use and the system
was applied to the upper arm. No other pain
medications were used. Although the skin was
normal, the system initially did not have good
contact and then was successfully readjusted
and adherence was then fine. Once the system
was readjusted, his pain level quickly improved.
The patient used two fentanyl ITS systems. On
POD 1, the patient administered 19 doses of
fentanyl; the number of doses decreased on
POD 2, and the fentanyl ITS was used for most
of that day and then discontinued. There was
some slight skin redness at both administration
sites where the system had been applied, but
resolved without intervention within 24 h. The
patient was then transitioned to PO
hydrocodone/acetaminophen. On POD 4, the
patient was discharged. The patient reported
that he was very satisfied with the pain control
that the system provided once it was adhered to
his skin.
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PROSTATE
Case 6
A 61-year-old male patient (BMI 28 kg/m2) with
prostate cancer underwent a laparoscopic,
robotic-assisted prostatovesiculectomy. He had
a history of hypertension and hypercho-
lesterolemia. Metamizole 1.25 g IV was given as
a prophylactic non-opioid analgesic for
postoperative pain. No analgesic medication
was administered in the recovery room;
however, the patient did receive 75 mcg of
clonidine. Fentanyl ITS was applied at the
upper left arm (right-handed patient) and the
patient self-administered 41 doses. The patient
received two IV pushes of piritramide 75 mg for
breakthrough pain (a synthetic opioid analgesic
with approximately two-thirds of the analgesic
potency of morphine). In addition, 4 g of
metamizole was used as part of a multimodal
analgesia plan. Once the patient discontinued
fentanyl ITS,hewas transitioned toPOmorphine
10 mg PRN. The patient experienced nausea and
vomiting approximately 2 h after initiating
fentanyl ITS; the nausea was associated with the
IV administration of piritramide and was
successfully treated with metoclopramide and
granisetron. There were no skin irritations or
other systemic side effects reported. The patient
was very satisfied with the ease-of-use of the
fentanyl ITS system. The patient indicated that
he would like to use the same pain management
regimen in the future if he ever needed another
surgery.
Case 7
A 67-year-old male patient (BMI 25 kg/m2) with
benign prostatic hypertrophy underwent open
suprapubic resection of the prostate gland. Prior
to surgery, he had urinary retention due to the
hypertrophy that resulted in acute kidney
failure requiring hemodialysis. He had been in
the ICU due to substantial renal fluid loss ([30 l
per day). He also had a history of hypertension
and hypercholesterolemia. He was not a
candidate for etoricoxib or morphine due to
its active metabolite, considering the acute
kidney failure. Metamizole IV was given as a
prophylactic non-opioid analgesic for
postoperative pain. The patient was titrated to
comfort with 10 mg piritramide (synthetic
opioid); then fentanyl ITS was applied to the
upper left arm (right-handed patient) for 24 h
and the patient administered 47 doses. No
breakthrough opioid medication was required
during the fentanyl ITS dosing. The patient
received concomitant metamizole 4 g over the
first 24 h. Once the patient discontinued
fentanyl ITS he was transitioned to PO
oxycodone PRN and metamizole. There was
no skin irritation or other systemic side effects
reported. The patient found the system very





Overall, the clinicians interviewed felt that
fentanyl ITS was easy to use for their patients.
The patients in this case series consistently
reported to their clinician that the product
was easy to use. Nurses expressed relief at not
having to program PCA settings or manage an
additional IV line (or any IV line). One site also
indicated that the use of fentanyl ITS with its
fixed dosing is an asset as it eliminated
unnecessary programming and variability in
postoperative pain management. In addition,
the physical therapists (physiotherapists)
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managing the prostate surgery patients noted
that mobilizing patients was much easier
without an IV line. Fentanyl ITS also reduced
issues with IV access and workload associated
with IV PCA devices.
Training
The sites emphasized the importance of staff
training on how to manage the system. For
example, at the site where the bariatric surgeries
are conducted, all clinical team members (not
limited to the physicians and nurses) who see
these patients are trained on fentanyl ITS which
allows them to reinforce the training when they
see the patient. Also, the center now places a
sign above each patient’s bed that says ‘‘IONSYS
in place’’ as a reminder for the clinical staff to
reinforce the key training points with the
patients.
Patient Selection
The fentanyl ITS development program enrolled
a broad range of surgery types. The labeled
indication includes patients with
moderate-to-severe postoperative pain without
specification as to surgery type. However, when
the phase 3 clinical studies were conducted,
bariatric surgery was relatively uncommon. In
this case series, three patients had bariatric
surgical procedures with BMI ranging from 37
to 58 kg/m2. Fentanyl ITS was safe and effective
for all three, supporting previous data [15] that
higher BMI patients with postoperative pain
can be appropriately treated with the system.
Moreover, consistent with the characteristics of
this patient population, all three bariatric
patients had a history of sleep apnea and none
developed signs of clinically relevant respiratory
depression while fentanyl ITS was administered.
Clinicians must routinely balance the
benefit-risk of opioid postoperative pain
management with the potential for respiratory
depression.
Several of the patients in these case series
had significant medical histories and
co-morbidities. Two of the patients had a
complicated hospital course prior to fentanyl
ITS treatment: renal failure and silent MI. These
experiences build upon the phase 3 study results
and further show that fentanyl ITS can be used
for pain management in more complex
postoperative patients, within the parameters
of the Prescribing Information.
Six of the seven cases were elective or
semi-elective surgeries; the perirectal abscess
case was an emergent case performed at night.
This case was also managed successfully with
fentanyl ITS and showed that training the staff
in advance can enable appropriate use of the
device in surgeries that are not pre-planned.
Titration to Comfort before Initiating
Fentanyl ITS
It was repeatedly noted that patients responded
better to fentanyl ITS if they were titrated to
comfort prior to initiation, which is consistent
with the Prescribing Information for fentanyl
ITS. These clinicians initiated fentanyl ITS on
the medical-surgical unit because they found
that patients in the PACU may be too sedated to
understand or operate the system, although the
system can be applied in the PACU or on the
patient floor.
Breakthrough Pain
In this series, most patients did not require
additional analgesic medication during fentanyl
ITS administration; however, the sites reported
that it is worthwhile to have PRN orders of
opioids and/or NSAIDs to assist with
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breakthrough pain in case it is required.
However, it is important to remember that the
concomitant use of fentanyl ITS with other
central nervous system depressants can increase
the risk of respiratory depression and therefore
the clinicians must monitor patients even more
closely if using a concomitant opioid.
Medication after Fentanyl ITS
Once patients were able to progress beyond
parenteral opioids, they were easily transitioned
from fentanyl ITS to the clinician’s standard
pre-discharge oral analgesia regimen. Most were
switched to the combination of hydrocodone
and acetaminophen. This allowed fentanyl ITS
to be readily incorporated into each center’s
standard-of-care pain management regimen.
Application Site
When applying fentanyl ITS, it is important to
press and hold the system firmly in place, with
the sticky side down, onto the patient’s skin for
at least 15 s. However, occasionally, the system
may loosen from the skin and if this occurs, it
should be secured to the patient’s skin by
pressing the edges with fingers or securing
with a non-allergenic tape to make sure that
all edges have complete contact with the skin. It
is important to remember not to place tape over
the button, light, or digital display.
Application Site Skin Reactions
Consistent with the fentanyl ITS Prescribing
Information, some patients experienced redness
at the application site. In this case series, none
of the site reactions were severe; none required
intervention or discontinuation of the product.
It is important to train and alert the clinical staff
that this can be an adverse event associated
with fentanyl ITS use; however, it is typically
self-limited.
DISCUSSION
Adequate analgesia in the postoperative setting
is an integral part of patient recovery following
surgery. Opioids continue to be a valuable
component of multimodal treatment. As with
all opioid medications, clinicians using fentanyl
ITS should carefully select, monitor, and
manage their patients for opioid-related
adverse effects.
This report describes seven cases in clinical
practice using fentanyl ITS for the management
of post-operative pain in the acute care
postoperative hospital setting. All patients
described in this cases series were prescribed
fentanyl ITS consistent with the Prescribing
Information. In all cases, fentanyl ITS was
effective, easy to use, and well tolerated; skin
reactions were reported in two of the patients
and were self-limited. This series details the
differences in patient experiences based upon
surgery type and shows the versatility of the
fentanyl ITS system. For example, the
laparoscopic bariatric surgery patients required
24 h or less of fentanyl ITS before conversion to
PO opioids. Whereas, the patients who
underwent colorectal surgery used the system
for up to 3 days.
The main limitations of this case series are
that the data was collected retrospectively in a
small number of patients. However, the
questionnaire was standardized and attempted
to provide consistent information. The data
collected in this case series were consistent with
the phase 3 trials as well as the Prescribing
Information and should provide treating
clinicians with added confidence about the
overall efficacy and safety of fentanyl ITS.
246 Pain Ther (2016) 5:237–248
CONCLUSIONS
The clinical findings from the case studies are
consistent with the data from the randomized
clinical trials for fentanyl ITS in the
management of postoperative pain. This case
series adds to the clinical experience with
fentanyl ITS and gives specific details of its use
in recent patients who have undergone
bariatric, colorectal, perirectal, or prostate
surgeries. The efficacy and safety profile
observed in these case studies was consistent
across surgery types and patient characteristics.
Perhaps most importantly, these reports
support that the system can be practically
integrated into current pain management
regimens, including multimodal therapy and
the subsequent switch to oral analgesics.
Fentanyl ITS is a new patient-controlled
option for postoperative pain management
across a range of complex surgery and
patient types, that may enable postoperative
recovery.
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